ICON PLC - Asset Resilience Ratio
ICON PLC (ICLR) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ICLR working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2025)
This chart shows how ICON PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ICLR current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down ICON PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ICLR long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: ICON PLC maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
ICON PLC Industry Peers by Asset Resilience Ratio
Compare ICON PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 13.87% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 41.08% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for ICON PLC (1998–2025)
The table below shows the annual Asset Resilience Ratio data for ICON PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $16.27 Billion | -- |
| 2024-12-31 | 0.00% | $0.00 | $16.88 Billion | -- |
| 2023-12-31 | 0.01% | $1.95 Million | $16.99 Billion | +0.00pp |
| 2022-12-31 | 0.01% | $1.71 Million | $17.19 Billion | +0.00pp |
| 2021-12-31 | 0.01% | $1.71 Million | $17.39 Billion | -0.04pp |
| 2020-12-31 | 0.05% | $1.73 Million | $3.44 Billion | -1.66pp |
| 2019-12-31 | 1.71% | $49.63 Million | $2.91 Billion | -0.80pp |
| 2018-12-31 | 2.51% | $59.91 Million | $2.39 Billion | -1.04pp |
| 2017-12-31 | 3.55% | $77.59 Million | $2.19 Billion | -0.18pp |
| 2016-12-31 | 3.73% | $68.05 Million | $1.83 Billion | -1.28pp |
| 2015-12-31 | 5.00% | $85.99 Million | $1.72 Billion | -1.35pp |
| 2014-12-31 | 6.36% | $97.10 Million | $1.53 Billion | -3.23pp |
| 2013-12-31 | 9.59% | $138.32 Million | $1.44 Billion | +3.25pp |
| 2012-12-31 | 6.34% | $76.18 Million | $1.20 Billion | +1.03pp |
| 2011-12-31 | 5.31% | $54.94 Million | $1.04 Billion | -0.11pp |
| 2009-12-31 | 5.42% | $49.23 Million | $908.40 Million | +0.49pp |
| 2008-12-31 | 4.93% | $42.73 Million | $867.28 Million | -1.10pp |
| 2007-12-31 | 6.02% | $41.75 Million | $693.14 Million | -2.34pp |
| 2006-12-31 | 8.36% | $39.82 Million | $476.34 Million | +1.83pp |
| 2005-12-31 | 6.53% | $22.81 Million | $349.07 Million | -0.35pp |
| 2004-12-31 | 6.88% | $23.09 Million | $335.32 Million | +1.07pp |
| 2003-12-31 | 5.82% | $10.88 Million | $186.92 Million | -6.67pp |
| 2001-12-31 | 12.49% | $18.52 Million | $148.32 Million | -18.47pp |
| 2000-12-31 | 30.96% | $34.32 Million | $110.87 Million | +9.58pp |
| 1999-12-31 | 21.38% | $21.41 Million | $100.12 Million | -16.89pp |
| 1998-12-31 | 38.27% | $35.90 Million | $93.80 Million | -- |
About ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It… Read more